Author of

• 13548

  +

  P1.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 212)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Locoregional Disease – NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 13556

    +

    P1.03-008 - Weekly Carboplatin/Gemcitabine + Concurrent Thoracic RT Followed by Consolidation Carboplatin/Gemcitabine for Inoperable Stage III NSCLC (ID 994)

    09:30 - 09:30  |  Author(s): S. Casado
    • Abstract

    Background:
    Concurrent chemo and radiotherapy (CT- RT) is standard of care for inoperable stage IIIA/B non-small cell lung cancer (NSCLC). Optimal regimen and schedule of concurrent CT- RT remain undefined. This phase II trial evaluated carboplatin –gemcitabine + concurrent RT followed by consolidation carboplatin – gemcitabine
    
    Methods:
    Treatment schedule during CT-RT phase: weekly carboplatin (AUC 2) + gemcitabine (200mg/m2) for 6 weeks + concurrent RT (60 Gy). CT consolidation phase: carboplatin (AUC 3) gemcitabine (2500 mg/m2) every two weeks for 3 cycles. Primary endpoint was security and secondary response rate, time to progression (TTP) and overall survival (OS)
    
    Results:
    24 patients were enrolled: Sex 18 male, 6 female. Histology: 12 adenocarcinoma, 8 squamous, 4 undifferentiated large cell carcinoma. Stage: IIIB: 20, IIIA: 4. ECOG 0-1: 23, ECOG 2: 1. All the patients completed concurrent CT-RT and 22 consolidation CT. Toxicity: CT- RT phase: No grade 4 toxicity was observed. Grade 3: Neutropenia 0, anemia 4.1%, thrombocytopenia 12.5%, esophagitis 16.6%. CT consolidation phase: Grade 3-4 toxicity: Neutropenia 16.6%, Anemia 21%, Thrombocytopenia 16.6% of the patients. 3 patients required red blood cell transfusion and 1 patient died for febrile neutropenia grade 4 during consolidation. Efficacy: Response Rate: 75% (Partial: 50% Complete: 22%), Stable disease 21% Progression 4%. Median TTP: 11 months (95% CI 7-17) and median OS: 18 months (95% CI 16.2- 20.5)
    
    Conclusion:
    Concurrent carboplatin – gemcitabine with thoracic RT is feasible with a favorable profile showing less hematologic toxicity and esophagitis than other CT-RT regimens. CT consolidation showed severe hematological toxicity. This regimen is active and could be a good option to combine with concurrent RT.